

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David White
Application No.: Group No.: N/A
Filed: Herewith Examiner: N/A
For: COMPOSITIONS, KITS AND METHODS FOR PROGNOSTICATION,
DIAGNOSIS, PREVENTION, AND TREATMENT OF BONE-RELATED
DISORDERS AND OTHER DISORDERS

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (3 pages)
- 3.. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*


I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a) **37 C.F.R. SECTION 1.10***
- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EL992152675US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: September 18, 2003

Sean Hunziker
(type or print name of person certifying)

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No.: 09/ 628,495, filed on July 28, 2000.

The following references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, in the event additional copies are necessary, the undersigned will submit such copies upon request.

September 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	
Sheet	1	of	1
		Herewith	David White
		N/A	N/A
		N/A	MP199-130P1RCN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C1	Alberts et al., <i>Molecular Biology of the Cell</i> , Garland Publishing, Inc. 1 st Ed.:127-141 (1983)	
	C2	Blechschimidt et al., GenBank Accession No. AF003625, January 1, 1998	
	C3	Cardinali et al., <i>J. Pineal Res.</i> 34:81-87 (2003)	
	C4	Conway, S. et al., <i>Journal of Biological Chemistry</i> 275(27):20602-20609 (2000)	
	C5	DeRienzo et al., <i>Perspective in Comparative Endocrinology</i> :1075-1079 (2001)	
	C6	Drew et al., <i>J. Neuroendocrinol.</i> 10:651-661 (1998)	
	C7	Gubitz et al., GenBank Accession No. AAC21462, March 2, 1999	
	C8	Gubitz et al., <i>Genomics</i> 55:248-251 (1999)	
	C9	Gubitz et al., <i>Genomics</i> 55(2):248-251 (1999)	
	C10	Lewin Genes II, <i>John Wiley & Sons, Inc.</i> :221-236 (1985)	
	C11	McDougall et al., <i>Endocrinology</i> 144(5):1994-1999 (2003)	
	C12	Murray et al., <i>Harper's Biochemistry</i> , Appleton & Lange 21 st Ed. Chapters 10, 11 and 41 (1990)	
	C13	Peterlik, M. et al., <i>Experimental Gerontology</i> 32(4-5):577-586 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Name of Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	
				MPI99-130P1RCN1M	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C14	Reppert et al., GenBank Accession No. U52218, July 28, 1996	
	C15	Reppert et al., GenBank Accession No. U52219, July 28, 1996	
	C16	Reppert et al., <i>FEBS Lett.</i> 386:219-224 (1996)	
	C17	Reppert, S. M., et al., <i>FEBS Lett.</i> 386(2-3):219-224 (1996)	
	C18	Rodan, <i>Bone</i> 13:S3-S6 (1992)	
	C19	Roth et al., <i>J. Biol. Chem.</i> 31:22041-22047 (1999)	
	C20	<i>Stedman's Medical Dictionary</i> , Physicians' Desk Reference, Medical Economics Company Inc. (2002)	
	C21	Stein, W. D., <i>Channels, Carriers, and Pumps: An Introduction to Membrane Transport</i> , Academic Press 1st Ed. Chapter 3: Ion Channels Across Cell Membranes:73-125 (1990)	
	C22	Weaver and Reppert, <i>NeuroReport</i> 9:109-112 (1996)	
	C23	Wiren et al., <i>J. Endocrinol.</i> 175(3):683-694 (2002)	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.